Nashville, Tenn.-based Vanderbilt-Ingram Cancer Center hematologists have developed guidelines for implementing outpatient immunotherapy treatment of CAR-T and bispecific antibodies.
The guidelines were published Dec. 4 in JCO Oncology Practice.
BsAb and CAR-T elicit strong immune responses and “typically require inpatient monitoring, which can be an economic and logistical burden for both patients and hospitals,” according to a Jan. 12 news release from Vanderbilt University Medical Center.
The recommendations offer strategies to optimize clinical infrastructure and workflows, while emphasizing the importance of patient and caregiver education surrounding remote monitoring.
Read the full guidelines here.
Leave a Reply